Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes

JOURNAL OF CONTROLLED RELEASE

卷:217

Article

Pardi, Norbert¹  Tuyishime, Steven¹  Muramatsu, Hiromi¹  Kariko, Katalin¹  Mui, Barbara L.²  Tam, Ying K.²  Madden, Thomas D.²  Hope, Michael J.²  Weissman, Drew¹ 

[1] Univ Penn, Dept Med, Philadelphia, PA 19104 USA

[2] Acuitas Therapeut, Vancouver, BC V6T 1Z3, Canada

关键词: mRNA;    Pseudouridine;    Luciferase;    Nanoparticle;    Non-viral gene delivery;   

DOI  :  10.1016/j.jconrel.2015.08.007

来源: Elsevier

【 摘 要 】

In recent years, in vitro transcribed messenger RNA (mRNA) has emerged as a potential therapeutic platform. To fulfill its promise, effective delivery of mRNA to specific cell types and tissues needs to be achieved. Lipid nanoparticles (LNPs) are efficient carriers for short-interfering RNAs and have entered clinical trials. However, little is known about the potential of LNPs to deliver mRNA. Here, we generated mRNA-LNPs by incorporating HPLC purified, 1-methylpseudouridine-containingmRNA comprising codon-optimized firefly luciferase into stable LNPs. Mice were injected with 0.005-0.250mg/kg doses ofmRNA-LNPs by 6 different routes and high levels of protein translation could be measured using in vivo imaging. Subcutaneous, intramuscular and intradermal injection of the LNP-encapsulated mRNA translated locally at the site of injection for up to 10 days. For several days, high levels of protein production could be achieved in the lung from the intratracheal administration of mRNA. Intravenous and intraperitoneal and to a lesser extent intramuscular and intratracheal deliveries led to trafficking of mRNA-LNPs systemically resulting in active translation of the mRNA in the liver for 1-4 days. Our results demonstrate that LNPs are appropriate carriers for mRNA in vivo and have the potential to become valuable tools for delivering mRNA encoding therapeutic proteins. (c) 2015 Elsevier B.V. All rights reserved.

【 授权许可】

Free